Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc.'s Q·Score is 6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: currently unprofitable (-57% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for BEAM is $51.20, based on ratings from 15 Wall Street analysts. This is 66.8% above the current price of $30.70. Price targets are forward-looking estimates and not guarantees of future performance.

Beam Therapeutics Inc. (BEAM) scores in line with sector averages on valuation metrics. The consensus analyst price target of $51.20 is 67% above the current price.

Beam Therapeutics Inc. is scheduled to report earnings in 2 days, on May 5, 2026.

Beam Therapeutics Inc. has a net profit margin of -57.2%, indicating the company is currently operating at a net loss. Its gross margin stands at -193.1%, reflecting a more cost-intensive business model.

Beam Therapeutics Inc. is reporting strong year-over-year growth of 279.5%.

Beam Therapeutics Inc. has a debt-to-equity ratio of 0.12×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 13.09×, indicating comfortable short-term liquidity.